ArticleLife (Basel, Switzerland)2024
Clinicopathological Studies on the Impact of Grape Seed Extract and L-Carnitine as Cardioprotective Agents Against Doxorubicin-Induced Toxicity in Rats.
Article in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cardioprotective Potential of Grape-Derived Polyphenols in Cancer Therapy-Related Cardiotoxicity.International journal of molecular sciences · 2026Review
- Bridging Gaps in Heart Failure Science: Toward a More Integrated Future.Life (Basel, Switzerland) · 2025Article
- EvaluatingBiomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Doxorubicin (DOX) cancer therapy induces serious cardiotoxicity as a side effect. This study aimed to investigate the cardioprotective effects of grape seed extract (GSE) and L-Carnitine (L-CA) against DOX-induced cardiac toxicity in male rats. Six groups of male albino rats were used: G1 (control); G2 (GSE), given grape seed extract (100 mg/kg b.wt.) orally for 35 days; G3 (L-CA) (150 mg/kg b.wt.); Group 4 (DOX-induced cardiotoxicity), given DOX (10 mg/kg b.wt., i.p.) on the 28th day of the experiment; G5 (GSE + DOX), given GSE and DOX as previously mentioned; and G6 (L-CA + DOX), given L-CA and DOX as previously mentioned. Electrocardiographic evaluation, lipid profile, lipid peroxidation and antioxidants, serum cardiac markers, and inflammatory markers were estimated. Histopathological evaluation of cardiac tissue was also examined. Key findings showed that DOX induced ECG abnormalities lipid peroxidation, reduced antioxidants, and elevated cardiac and inflammatory markers. GSE and L-CA significantly ameliorated ECG abnormalities, reduced lipid peroxidation, improved antioxidant enzymes and serum cardiac markers, and reduced inflammation. These findings suggest that GSE and L-CA exhibit substantial cardioprotective effects in DOX-induced cardiotoxicity via their antioxidant and anti-inflammatory potentials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.